In longer-term studies, such as STEP 5, participants maintained an average weight loss of 15.2% after 104 weeks with semaglutide 2.4 mg, compared to just 2.6% with placebo
The OGTT is now the preferred diagnostic test for dumping syndrome 1,20,85
Clinical research shows that tirzepatide, a dual GLP-1 and GIP receptor agonist, significantly quiets this mental interference by regulating appetite centers in the brain
Safety, side effects, and who should pause before starting All GLP-1 receptor agonists and the GIP/GLP-1 dual agonist tirzepatide share a well-characterized side-effect profile: nausea, vomiting, diarrhea, constipation, abdominal pain, and headache are common
If regurgitation occurs, the sedated patient cannot effectively clear their airway, allowing gastric contents to enter the lungs
Semaglutide works by mimicking the hormone glucagon-like peptide 1 (GLP-1), and is currently authorised for the treatment of type 2 diabetes patients with insufficient glycaemic control and long-term weight management